Exploring the role of immune and genetic factors in bipolar disorder and schizophrenia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the connection between Human Endogenous Retroviruses (HERV-W) and the development of bipolar disorder and schizophrenia by examining immune responses and environmental influences. It aims to identify new biomarkers that correlate with clinical profiles and immunological markers, potentially leading to innovative treatment approaches. The research involves blood sampling to assess levels of specific viral proteins and genetic variants in patients with these psychiatric disorders. By combining clinical, viral, immunological, and genetic methodologies, the study seeks to enhance our understanding of the pathophysiological mechanisms underlying these conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Bipolar disorder or Schizophrenia (according to Diagnostic and Statistical Manual of Mental Disorders IV)

Exclusion Criteria:

* pregnant women
* Vaccination within 4 precedent weeks
* Severe neurologic illness
* Immunosuppressing or immuno-modulating treatment.
* Infectious disease within 4 precedent weeks (including HIV 1 et 2, Hepatite B, C)
* Refuse to have HIV and hepatite B et C tests or to be informed of their results

Where it's running

• Psychiatry Department of Mondor Hospital
  Créteil, France, France Recruiting
• Clinical Investigations Center of Mondor Hospital
  Créteil, France Recruiting
• Psychiatry Department of Widal Hospital
  Paris, France Recruiting
• EPS Maison Blanche
  Paris, France Recruiting
• Psychiatry Department of R. Dubos Hospital
  Pontoise, France Recruiting
• Psychiatry Department of Perrens Hospital
  Bordeaux, France Not yet recruiting

Study contacts

• Study coordinator: Marion Leboyer, Pr
• Email: marion.leboyer@fondation-fondamental.org
• Phone: (33) 1 49 81 38 22

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Effects of comorbidity on people with severe mental illness

  This study tests how having both alcohol/substance use and a severe mental illness affects hospitalizations, medications, and social participation among adults followed at a mental health center.

  Recruiting Abant Izzet Baysal University · Bolu, Bolu · NCT07692984

• Venous Tourniquet with Low-Dose Sugammadex vs Arterial Tourniquet for Seizure Monitoring During ECT

  40 patients undergoing ECT will have a venous tourniquet on one arm and an arterial tourniquet on the other to see which method better reveals motor seizures.

  Recruiting Medipol University · Istanbul · NCT07534475

• 7T MRI and visual perception markers for severe mood and psychotic disorders

  This project tests whether 7‑tesla MRI scans combined with visual perception tests can identify brain markers linked to diagnosis and treatment outcomes in adults with major depressive disorder, bipolar disorder, or schizophrenia.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07479758

• Emotional Eating, Sleep Quality, Mental State, and Metabolic Syndrome in Psychiatric Patients

  This study tests how mood, sleep, and emotional eating relate to metabolic syndrome in people with schizophrenia or bipolar disorder.

  Recruiting Abant Izzet Baysal University · Bolu, Bolu · NCT07411222

• À deux, c'est mieux — group program to improve romantic relationships for young adults with severe mental illness

  This program will try a 12-week, small-group course to help single adults with severe mental illness build skills for dating, communication, and closer social relationships.

  Recruiting at 2 sites Centre hospitalier de Ville-Evrard, France · Épinay-sur-Seine, Île-de-France Region and 1 other locations · NCT07316803

• Valbenazine for adults with tardive dyskinesia who remain symptomatic on or after a VMAT2 inhibitor

  This trial will test whether valbenazine reduces involuntary movements in adults with tardive dyskinesia who still have symptoms while taking or after stopping a VMAT2 inhibitor.

  Recruiting at 19 sites Phase 4 Neurocrine Biosciences · Bryant, Arkansas and 18 other locations · NCT07105111

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.